As a result, patients who don’t fit the average, like Simon, may have difficulty gaining access to the treatment best for them.  For a patient like Simon, diagnosed with late stage and rapidly advancing colorectal cancer, the specific course of treatment has real implications. Simon’s tumor has a specific genetic variant (wild type KRAS), which means he is more likely to respond to specific targeted treatments. Not all treatments are the same, and for Simon, the specific treatment matters.

Selecting the right treatment depends on a variety of clinical factors, as well as needs, characteristics and preferences specific to an individual patient. Medicare Part B was set up to allow physicians to make the best decisions for their patients, offering a wide range of treatment options for patients suffering from serious illnesses, including cancer, rheumatoid arthritis, autoimmune disorders and more.

This proposal would come between providers and patients by allowing the government to make one-size-fits all value judgments about the best care for Medicare patients.  As new medicines become available, especially new targeted and personalized medicines, like President Jimmy Carter’s recent cancer treatment, Medicare physicians and patients should have those options available to them.

This proposal is mandatory and nationwide, which marks a dramatic departure from CMMI’s usual, voluntary testing approach. Rather, this model flies in the face of testing by making changes to payment for nearly all Part B medicines and mandating participation for three in four Medicare Part B providers in diverse settings, including hospital outpatient departments, physician offices and pharmacies. As a result, this model will affect care for Medicare patients across the country. Physicians treating the sickest patients could have their reimbursement cut dramatically, disproportionately impacting specialists who treat complex diseases.

Leave a Reply

Your email address will not be published. Required fields are marked *